Until now, COPD patients have had few options for managing their symptoms. As a participant in this study, you may see improved control of your COPD symptoms and help others with COPD to breathe easier in the future.

You may be eligible for this study if:

  • You have moderate to severe COPD
  • You are between the ages of 40 and 75 years
  • You have not smoked for at least 2 months prior to your screening interview

These are not the only eligibility requirements for this study and certain other criteria may exclude you.

How the study works

1. Eligibility Interview

Interested patients contact the study site to go through a list of eligibility requirements. If you are eligible, a member of the study team will invite you to come in for an initial screening examination.

2. Medical Screening

The study doctor or staff will review the study in detail, any known risks or benefits, your rights as a participant and other information you may need to make a decision. An initial medical screening will be performed and if you meet the initial eligibility requirements you may be scheduled for further evaluation. The healthcare provider will provide a full description of study requirements.

3. The Procedure

The one-time non-surgical procedure involves passing a special catheter through a standard bronchoscope into the lungs. The catheter delivers a type of electrical energy called radiofrequency (RF) energy to the nerves located on the outside of the airways. Once the energy has been delivered, the catheter and bronchoscope are removed. The procedure takes about one hour. Learn more about the procedure.

4. Costs, Care and Follow-up Visits

All physician visits and medical visits are provided at no cost to you.

All trial participants will be under the care of a trial doctor, who is a lung specialist, for the entire time on the trial.

Your status will be monitored for three years after the procedure. You will be able to contact the research team throughout this time period to address any questions or concerns.

Enrollment of the AIRFLOW-2 Clinical Trial has been completed. Please contact us if you have a question.

For more information about clinical trials, the following websites may be useful:

Clinical Trials US National Institutes of Health
EU Clinical Trials Register
UK Clinical Trials Gateway
World Health Organization International Clinical Trials Registry Platform

This post is also available in: French German Dutch